Lansforsakringar Fondforvaltning’s Edwards Lifesciences EW Stock Holding History

Lansforsakringar Fondforvaltning’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-188,318	Closed	-$15.1M	–	604
2026 Q1	$15.1M	Sell	188,318 -1,078	-0.6%	-$88.9K	0.08%	207
2025 Q4	$16.1M	Sell	189,396 -83,927	-31%	-$6.89M	0.08%	196
2025 Q3	$21.3M	Buy	273,323 +10,747	+4%	+$840K	0.11%	158
2025 Q2	$20.5M	Sell	262,576 -18,295	-7%	-$1.36M	0.12%	155
2025 Q1	$20.4M	Sell	280,871 -15,846	-5%	-$1.13M	0.12%	149
2024 Q4	$22M	Buy	+296,717	New	+$20.8M	0.12%	142

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Lansforsakringar Fondforvaltning's EW Position: Q2 2026 in Review

Lansforsakringar Fondforvaltning sold out of Edwards Lifesciences (EW) in Q2 2026, closing a stake of 188,318 shares — an estimated $15.1M sold.

Lansforsakringar Fondforvaltning first reported a position in EW in Q4 2024 and held it in 6 quarters. The position peaked at $22M in Q4 2024. 1,338 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Lansforsakringar Fondforvaltning reported no remaining Edwards Lifesciences position as of Q2 2026 after selling out during the quarter.
Lansforsakringar Fondforvaltning sold 188,318 Edwards Lifesciences shares in Q2 2026, an estimated $15.1M.
Lansforsakringar Fondforvaltning first reported a position in Edwards Lifesciences in Q4 2024 and held it in 6 quarters.
Lansforsakringar Fondforvaltning's Edwards Lifesciences position peaked at $22M in Q4 2024.
1,338 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Lansforsakringar Fondforvaltning's 13F filing for Q2 2026, filed 13 Aug 2026.